The genes HMOX1, FFAR2, CD14, GPX1, KMO, IL10, ALOX5, CPT1A, and SGK1 showed similar expression patterns and were clustered together with upregulation initially after LPS injection and subsequent downregulation
While differences compared to placebo were often statistically significant within the first few months, the *peak average weight loss* was typically observed after many months (closer to a year or more) of continuous treatment at stable maintenance doses, combined with diet and exercise
This review explores the role of GLP-1 RAs in the treatment of obesity, with particular attention to their potential and limitations in individuals with or without comorbid BED, subclinical disordered eating patterns, and with co-occurring mental health conditions
No head-to-head Phase 3 trial has been run between retatrutide and tirzepatide yet, so I'm careful not to claim retatrutide's Phase 3 numbers directly outperform tirzepatide's they are cross-trial comparisons
Association between physical activity and risk of gastroesophageal reflux disease: A systematic review and meta-analysis